An acellular pertussis vaccine in healthy adults: safety and immunogenicity

This publication has 37 references indexed in Scilit:

• Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
  The Lancet, 1997
• Safety and immunogenicity of Chiron/Biocine® recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers
  The Pediatric Infectious Disease Journal, 1997
• The Seroepidemiology of Bordetella pertussis Infections: A Study of Persons Ages 1-65 Years
  The Journal of Infectious Diseases, 1996
• Management of Healthcare Workers Exposed to Pertussis
  Infection Control & Hospital Epidemiology, 1994
• Acellular Pertussis Vaccines—A Solution to the Pertussis Problem?
  The Journal of Infectious Diseases, 1993
• Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old children
  The Journal of Pediatrics, 1992
• Development of an acellular pertussis vaccine and its administration as a booster in healthy adults
  Vaccine, 1991
• Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.
  The Journal of Experimental Medicine, 1990
• Acellular pertussis vaccine in adults: Adverse reactions and immune response
  European Journal of Clinical Microbiology & Infectious Diseases, 1987
• Intrafamilial spread of pertussis
  The Journal of Pediatrics, 1983